Jazz Pharmaceuticals is refocusing its sleep-disorder franchise after Axsome Therapeutics disclosed an FDA filing for AXS-12 in narcolepsy, highlighting Sunosi's move from Jazz's portfolio. Jazz shares have returned 119.3% over the past year and 42.3% over five years, with a 9.1% gain in the last month. The stock closed at $247.53, about 6% below the average analyst target, while Simply Wall St estimates a fair value of $257.00, suggesting the stock is slightly undervalued. Expected approvals for dordaviprone in H3 K27M-mutant diffuse glioma and Zepzelca in first-line small cell lung cancer maintenance are seen as key growth drivers, though risks include patent expirations and reliance on a few pipeline launches.
Axsome Therapeutics IncAxsome filed for FDA approval of AXS-12 in narcolepsy, a positive regulatory milestone.
Jazz Pharmaceuticals PLCAxsome's filing for AXS-12 in narcolepsy threatens Jazz's sleep franchise, prompting refocus.